Business Context and Reporting Period
This Form 8-K Current Report is filed by MedaSorb Technologies Corporation (noted as Cytosorbents Corp in metadata) for the reporting period ending December 31, 2007. The filing primarily addresses Item 5.02 regarding the appointment of principal officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation terms rather than financial performance data.
Material Changes
Effective December 31, 2007, the company entered into a new one-year Employment Agreement with Al Kraus, President and Chief Executive Officer, replacing his previous agreement. The principal terms include:
- Base Salary: $216,351 per annum.
- Equity Compensation: Quarterly issuance of options to maintain a 5% beneficial ownership interest on a fully diluted basis. This provision remains in effect until the company receives an aggregate of $4 million in financing following December 31, 2007.
- Termination Provisions:
- Death: Heirs receive 120 days of salary.
- Justifiable Cause: Accrued and unpaid base salary through termination date.
- Without Cause or Change of Control: One year's base salary payable monthly over one year.
- Restrictive Covenants: Prohibitions on disclosing confidential information, competing with the company, or soliciting customers/suppliers for one year post-termination, and soliciting employees for three years post-termination.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary on future operations. However, the equity compensation structure implies a material contingency: the company must secure $4 million in financing to alter the CEO's option grant schedule. The filing notes that the summary is qualified by the full text of the Employment Agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the company's current cash position and progress toward the $4 million financing threshold required to modify the CEO's equity grants.
- Review the full text of Exhibit 10.1 (Employment Agreement) for detailed definitions of "justifiable cause" and "Change of Control."
- Confirm the current fully diluted share count to assess the dilution impact of maintaining the CEO's 5% beneficial ownership interest.
- Check for any subsequent filings regarding the company's financing activities post-December 31, 2007.